

Cytos Biotechnology Ltd, 8952 Schlieren

Disclosure of shareholding pursuant to Art. 20 SESTA

Cytos Biotechnology Ltd (SIX:CYTN, the "Company"), Wagistrasse 25, 8952 Schlieren (Zurich) discloses pursuant to Article 20 of the Swiss Federal Act on Stock Exchanges and Securities Trading and the amendments to SESTO-FBC that came into force on December 1, 2007, that as of June 17, 2010, the Company has sale positions pursuant to Art. 13 para. 1 b SESTO-FBC of 1,131,680 written share purchase and written conversion rights, corresponding to 21.47% of voting rights of the shares registered in the Commercial Register of the Canton of Zurich.

The 1,131,680 written rights contain 731,680 share purchase rights of several employee stock option plans, which entitle holders of options after a vesting period of 2 years to purchase a total of 731,680 registered shares of the Company, corresponding to 13.88% of voting rights of the shares registered in the Commercial Register of the Canton of Zurich. Details of the options are as follows:

Year of allocation	Number of options	Exercise price in CHF	Exercise period ¹⁾ (number of years)
2002	137,618	79.50	10 ½
2002	37,581	42.46	10 ½
2005	833	39.85	5
2006	63,120	53.29	5
2007	64,842	117.83	5
2008	95,861	79.35	5
2009	148,496	33.42	5
2009	76,724	12.38	5
2010	94,605	14.05	5
2010	12,000	12.38	5

¹⁾ incl. vesting period of 2 years

The written conversion rights stem from the CHF 70 million 2.875% unsecured convertible bonds (due 2012). ISIN: CH0029060735. At the moment, the Company would have to issue 400,000 registered shares out of the conditional capital for the conversion of the convertible bonds at the present conversion price of CHF 175. These 400,000 registered shares represent 7.59% of voting rights of the shares registered in the Commercial Register of the Canton of Zurich. The conversion price can be adapted according to the conditions of the convertible bonds.

Due to partial repurchases of own convertible bonds (ISIN: CH0029060735) the Company owns purchase positions, pursuant to Art. 13 para. 1 b SESTO-FBC of CHF 28,875,000 convertible bonds representing 165,000 registered shares with 3.13% voting rights of the shares registered in the Commercial Register of the Canton of Zurich.

The contact person responsible at Cytos Biotechnology Ltd is Mr. Harry Welten.